Sun Pharmaceutical Industries

Quick check

The five things to look at first. Open one for more.

• DebtHighest safetyRated AAA by 2 agencies.
• ResultsGrowingIn the Jun 2026 quarter, sales rose 11% and profit rose 27% from a year earlier.
• DilutionNo new sharesNo new shares issued in the last year, so existing shareholders' slices were not cut.
• PromotersSteadyThe promoters (founders or parent) own 54% of the company, about the same as in Jun 2025.
• ValuationNormal for this stockThe share trades at 33.2 times its yearly earnings (P/E), cheaper than 55% of the time in the last 5 years. Its usual P/E is about 28.

Sun Pharmaceutical Industries against the typical company in its industry. The rank is out of the companies that report each figure; green means the better quarter of the pack, red the worse quarter.

• Valuation (P/E)33.2 against a typical 33.2: in line than most peers (1st = cheapest).111th of 220
• Sales growth+10.5% against a typical +15.6% from a year earlier.113th of 197
• Profit growth+26.5% against a typical +18.9% from a year earlier.74th of 160
• Share price, 3 months−12% against a typical −2%.148th of 200
• Size₹ 4,18,194.2 Cr. market value against a typical ₹ 507.7 Cr. (1st = largest).1st of 199

Exchange filings and their impact on the company.

• 26 Oct 2026Allotment of SecuritiesMedium impactNegativePrice −0.5% that day
  Sun Pharma raised Rs 7,816 cr via 5-year NCDs at 8.05-8.20%, more than doubling debt and adding ~Rs 638 cr annual interest.

  Sun Pharma on 26 October 2026 allotted Rs 7,816 crore of rated, listed unsecured NCDs on private placement, against a base size of Rs 7,000 crore plus Rs 816 crore greenshoe. Series A of Rs 2,003 crore pays 8.05% and Series B of Rs 5,813 crore pays 8.20%, both maturing 27 October 2031, with a put option on Series A in March 2028. The raise sharply increases gross debt and annual interest cost while purpose is not disclosed, weighing modestly on near-term earnings.

  Full analysisFiling
• 23 Oct 2026Press ReleaseLow impactPositivePrice −0.5% on 26 Oct
  Strong 2.5-year UNLOXCYT data shows durable complete responses with low toxicity, aiding niche uptake.

  Sun Pharma will present long-term follow-up data for UNLOXCYT (cosibelimab) at ESMO 2026 on October 24 from 205 advanced cutaneous squamous cell carcinoma patients with median follow-up of 2.5 years or more. Response rates were 51.3% and 44.4% in metastatic cohorts and 53.1% in locally advanced disease, with complete responses in 34.4% of locally advanced and 16.7-20.6% of metastatic patients, and 69-82% of responders still in response at two years with low high-grade immune side effects. The data reinforces durability and tolerability for the FDA-approved drug but implies only gradual uptake in a small niche relative to Sun Pharma's scale.

  Full analysisFiling
• 20 Oct 2026Press ReleaseLow impactPositivePrice +0.1% on 21 Oct
  NCCN preferred listing boosts UNLOXCYT adoption but moves the needle only slightly for Sun Pharma.

  Sun Pharma said its skin-cancer drug UNLOXCYT (cosibelimab-ipdl) has received a Category 2A Preferred designation in updated US NCCN guidelines for locally advanced cutaneous squamous cell carcinoma patients who cannot have curative surgery or radiation. Preferred status typically helps doctors prescribe the drug and helps with insurance coverage. For Sun Pharma, with annual sales of about Rs 58,462 crore, the benefit is positive but small in the next year as it ramps up US specialty sales.

  Full analysisFiling
• 12 Oct 2026Outcome of Board MeetingMedium impactNeutralPrice +0.6% on 13 Oct
  Sun Pharma board approved up to Rs 10,000 crore NCD framework, sharply raising leverage headroom with only small near-term earnings drag.

  Sun Pharma's board on 12 October 2026 approved issuance of listed, rated, unsecured redeemable non-convertible debentures up to Rs 10,000 crore on private placement in one or more tranches, leaving tranche terms to the Finance Committee. The board also noted the resignation of independent director Gautam Doshi effective 12 October 2026 for personal reasons. The NCD framework gives large debt headroom against FY26 borrowings of Rs 4,627 crore, with limited earnings impact until the funds are drawn and deployed.

  Full analysisFiling

Results dates and other board meetings. Full calendar

Compounded yearly rates over each period.

Listed companies in the same business.

Dilip Shantilal Shanghvi

Executive Chairman of the Board

Jayashree Satagopan

Chief Financial Officer

Aalok Dilip Shanghvi

Whole-time Director and Chief Operating Officer

Anoop Anjanikumar Deshpande

Compliance Officer, Company Secretary

Kirti Ganorkar

Managing Director

Vidhi Dilip Shanghvi

Whole-Time Director